Drug companies, patient groups, and academic stakeholders pressed the FDA to pause its Commissioner’s National Priority Voucher (CNPV) program during a public listening session, citing “deep concern” over the pilot’s speed and governance. The program, launched by former FDA commissioner Marty Makary, offers compressed FDA review timelines of roughly one to two months for products deemed aligned with vague “national priorities.” Most speakers argued the scheme should be returned to normal regulatory review processes with more public input and clearer criteria. Critics also questioned whether political considerations could influence decision-making, and said the pilot’s priority standards are not sufficiently defined. FDA officials acknowledged feedback and recommendations from 17 speakers across patient organizations, industry, and research groups, with some defending the program’s existing approvals while others raised process risks. The episode matters for biotech operators because CNPV could materially affect launch timelines, development planning, and how sponsors decide whether to pursue expedited pathways for high-value assets.